Market Report Source

Overview

With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:

• Stem Cell Therapeutics (Transplantation)
• Cord Blood Banking and
• Drug development

This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:

• Cardiovascular disease
• Lung disease
• Arthritis
• Incontinence
• Osteoporosis
• Diabetes
• Cancer
• Orthopedics
• Infertility
• Alzheimer’s disease
• Burns (severe)
• Lupus
• Parkinson’s disease
• Liver failure
• Multiple sclerosis
• Critical limb ischemia
• Crohn’s disease
• Sickle cell disease
• Multiple myeloma
• NH lymphoma
• Leukemia

Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:

• Aastrom Biosciences
• Advanced Cell Technologies
• Brainstorm Cell Therapeutics
• Celegene
• Cord Blood America
• Cord Blood Registry
• Cryo-Cell International
• ES Cell International
• Geron
• Harvest Technologies
• Invitrogen
• Medistem
• Neostem
• Opexa Therapeutics
• Osiris Therapeutics
• Plureon
• Regenetech
• Revivicor
• Stem Cell Sciences
• StemLifeLine
• ThermoGenesis
• VetCell Bioscience
• ViaCell

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

Scope and Methodology
Introduction
Current Stem Cell Therapies
Developmental Stem Cell Therapies
Issues in Stem Cell Research
Embryonic Stem Cells
Non-Embryonic Stem Cells
Stem Cell Forecasts

CHAPTER TWO: INTRODUCTION

The Promise of Stem Cells in Medical Treatment
Types of Stem Cells
Embryonic Stem Cells
Important Developments in ES Cell Research
Adult Stem Cells
Important Developments in AS Cell Research
Cord Blood Stem Cells
Stem Cell Harvesting
Embryonic Stem Cells
Therapeutic Cloning
Unfertilized Eggs
Adult Stem Cells
Leukapheresis
Peripheral Blood
Cord Blood Stem Cells
Transplantation Approaches
Allogenic Transplantation
Transplantation Procedures
Cancerous Stem Cells
Other Harmful Stem Cells
Stem Cells in Drug Development
Stem Cell Therapeutics
Stem Cell Targeting Drugs
Stem Cell Generated Organs

CHAPTER THREE: CURRENT STEM CELL THERAPIES

Cancer
Leukemia
Gene Therapy
Multiple Myeloma
Non-Hodgkin’s Lymphoma
Noncancerous Diseases
Aplastic Anemia
Immunodeficiency
Lupus
Sickle Cell Disease
Other Conditions

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

Stem Cells in Alzheimer’s Disease
Stem Cells in Arthritis
Stem Cells in Burns
Stem Cells in Cancer
Stem Cells in Cardiovascular Conditions
Stem Cells in Critical Limb Ischemia
Stem Cells in Crohn’s Disease
Stem Cells in Diabetes
Stem Cells in Incontinence
Stem Cells in Infertility
Stem Cells in Liver Failure
Stem Cells in Lung Disease
Stem Cells in Multiple Sclerosis
Stem Cells in Orthopedics
Stem Cells in Osteoporosis
Stem Cells in Parkinson’s Disease
Stem Cells in Sickle Cell Disease
Stem Cells in Best Case
Stem Cell Therapeutics
Fees Related to Drug Development
Most Likely Case
Stem Cell Therapeutics
Fees Related to Drug Development
Worst Case
Stem Cell Therapeutics
Umbilical Cord Blood Banking
Fees Related to Drug Development

CHAPTER FIVE: MARKET ANALYSIS

CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

Ethical Questions
Research Funding
Federal Funding
State Funding
International Initiatives
Stem Cell Patents

CHAPTER SEVEN: COMPANY PROFILES

Aastrom Biosciences
History and Lines of Business
Financial Information
Stem Cell Technology
Advanced Cell Technologies
History and Lines of Business
Financial Information
Stem Cell Technology
Brainstorm Cell Therapeutics
History and Lines of Business
Financial Information
Stem Cell Technology
Celegene
History and Lines of Business
Financial Information
Stem Cell Technology
Cord Blood America
History and Lines of Business
Financial Information
Stem Cell Technology
Cord Blood Registry
History and Lines of Business
Financial Information
Stem Cell Technology
Cryo-Cell International
History and Lines of Business
Financial Information
Stem Cell Technology
ES Cell International
History and Lines of Business
Financial Information
Stem Cell Technology
Geron
History and Lines of Business
Financial Information
Stem Cell Technology
Harvest Technologies
History and Lines of Business
Financial Information
Stem Cell Technology
Invitrogen
History and Lines of Business
Financial Information
Stem Cell Technology
Medistem
History and Lines of Business
Financial Information
Stem Cell Technology
Neostem
History and Lines of Business
Financial Information
Stem Cell Technology
Opexa Therapeutics
History and Lines of Business
Financial Information
Stem Cell Technology
Osiris Therapeutics
History and Lines of Business
Financial Information
Stem Cell Technology
Plureon
History and Lines of Business
Financial Information
Stem Cell Technology
Regenetech
History and Lines of Business
Financial Information
Stem Cell Technology
Revivicor
History and Lines of Business
Financial Information
Stem Cell Sciences
History and Lines of Business
Financial Information
Stem Cell Technology
StemLifeLine
History and Lines of Business
Financial Information
Stem Cell Technology
ThermoGenesis
History and Lines of Business
Financial Information
Stem Cell Technology
VetCell Bioscience
History and Lines of Business
Financial Information
Stem Cell Technology
ViaCell
History and Lines of Business
Financial Information
Stem Cell Technology

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Total Market for Stem Cell Technologies in $ Millions, 2007-2020

Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020

Table 1-3: Total Market for Cord Blood Banking Fees in $ Millions, 2007-2020

Table 1-4: Total Market for Stem Cell Drug Development Technologies in $ Millions, 2007-2020

CHAPTER THREE: CURRENT STEM CELL THERAPIES

Table 3-1: Types of Leukemia, 2007

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

Table 4-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007

Table 4-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020

Table 4-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020

Table 4-4: Types and Features of Urinary Incontinence, 2007

Table 4-5: Types and Causes of Male Infertility, 2007

Table 4-6: Common Diseases of the Lungs, 2007

CHAPTER FIVE: MARKET ANALYSIS

Table 5-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007

Table 5-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 – 2020

Table 5-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 – 2020

Table 5-4: Best Case: Cord Blood Banking Revenues in $ Millions, 2007-2020

Table 5-5: Best Case: Stem Cell-Based Drug Development Technology Fees, 2007-2020 (Preclinical Drug Candidates, Cost of Testing, Utilization of New Technology, Cost of New Technolgy per Drug)

Table 5-6: Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020

Table 5-7: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 – 2020

Table 5-8: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020

Table 5-9: Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2007-2020

Table 5-10: Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020

Table 5-11: Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020

Table 5-12: Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 – 2020

Table 5-13: Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020

Table 5-15: Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020

Table 5-16: Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020

ISSUES IN STEM CELL RESEARCH

Table 6-1: NIH Funding for Stem Cell Research in $ Million, 2003-2008 (est.)

Table 6-2: Positions on Human ES Cell Research by Country, 2007

COMPANY PROFILES

Table 7-1: Main Activities of Selected Stem Cell Companies, 2007

Table 7-2: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007